First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Conditions:   Mesothelioma, Malignant;   Mesothelioma, Malignant Pleural;   Mesothelioma Malignant Advanced Intervention:   Drug: Sintilimab+Anlotinib+Pemetrexed+Cisplatin Sponsor:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source:
Source: - January 12, 2022 Category: Research Source Type: clinical trials

Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
OSLO, Norway, Dec. 20, 2021. Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS of 25.0 months for treatment with ONCOS-102 in combination with... (Source: - Clinical Trials)
Source: - Clinical Trials - December 20, 2021 Category: Pharmaceuticals Source Type: clinical trials

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
Condition:   Mesothelioma, Malignant Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Carboplatin Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source:
Source: - November 29, 2021 Category: Research Source Type: clinical trials